StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Research analysts at StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Trading Down 4.6 %

Shares of NASDAQ:AEZS opened at $1.98 on Friday. The stock has a market capitalization of $9.60 million, a P/E ratio of -0.58 and a beta of 1.57. Aeterna Zentaris has a 1-year low of $1.36 and a 1-year high of $3.38. The business has a 50-day moving average price of $1.95 and a two-hundred day moving average price of $1.91.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.